[go: up one dir, main page]

CL2019001426A1 - Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. - Google Patents

Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.

Info

Publication number
CL2019001426A1
CL2019001426A1 CL2019001426A CL2019001426A CL2019001426A1 CL 2019001426 A1 CL2019001426 A1 CL 2019001426A1 CL 2019001426 A CL2019001426 A CL 2019001426A CL 2019001426 A CL2019001426 A CL 2019001426A CL 2019001426 A1 CL2019001426 A1 CL 2019001426A1
Authority
CL
Chile
Prior art keywords
compositions
pyridinoylpiperidine
methods related
ht1f agonists
ht1f
Prior art date
Application number
CL2019001426A
Other languages
English (en)
Inventor
Brigida Allieri
Paul Fagan
Emma Sharp
Raymond D Skwierczynski
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of CL2019001426A1 publication Critical patent/CL2019001426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS PSEUDOPOLIMORFOS DE LA SAL DE HEMISUCCINATO DE 2,4,6-TRIFLUORO-N-[6-(1-METIL-PIPERIDIN-4-CARBONIL)- PIRIDIN-2-IL]-BENZAMIDA QUE SON ÚTILES EN COMPOSICIONES FARMACÉUTICAS, POR EJEMPLO, PARA EL TRATAMIENTO Y PREVENCIÓN DE LA CEFALEA MIGRAÑOSA.
CL2019001426A 2016-12-06 2019-05-27 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. CL2019001426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
CL2019001426A1 true CL2019001426A1 (es) 2019-10-11

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001426A CL2019001426A1 (es) 2016-12-06 2019-05-27 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.

Country Status (38)

Country Link
US (1) US11053214B2 (es)
EP (1) EP3551617B1 (es)
JP (4) JP2020500936A (es)
KR (4) KR20190075130A (es)
CN (3) CN115385893A (es)
AU (1) AU2017373784B2 (es)
BR (1) BR112019010934A2 (es)
CA (1) CA3043772C (es)
CL (1) CL2019001426A1 (es)
CO (1) CO2019005290A2 (es)
CR (1) CR20190251A (es)
CY (1) CY1124540T1 (es)
DK (1) DK3551617T3 (es)
DO (1) DOP2019000139A (es)
EA (1) EA201991112A1 (es)
EC (1) ECSP19040190A (es)
ES (1) ES2889476T3 (es)
HR (1) HRP20211557T1 (es)
HU (1) HUE056820T2 (es)
IL (1) IL266598B2 (es)
JO (1) JOP20190129B1 (es)
LT (1) LT3551617T (es)
MA (1) MA52920B1 (es)
MD (1) MD3551617T2 (es)
MX (2) MX388091B (es)
MY (1) MY196855A (es)
NZ (1) NZ752906A (es)
PE (2) PE20241297A1 (es)
PH (1) PH12019501252B1 (es)
PL (1) PL3551617T3 (es)
PT (1) PT3551617T (es)
RS (1) RS62415B1 (es)
SI (1) SI3551617T1 (es)
TN (1) TN2019000174A1 (es)
TW (1) TWI671290B (es)
UA (1) UA124433C2 (es)
WO (1) WO2018106657A1 (es)
ZA (1) ZA201903449B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2413933T (lt) 2009-04-02 2018-02-26 Colucid Pharmaceuticals, Inc. 2,4,6-trifluor-n-[6-(1-metil-piperidin-4-karbonil)-piridin-2-il]-benzamidas, skirtas migrenos gydymui peroraliniu ar intraveniniu keliu
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
WO2022236004A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
LT2413933T (lt) 2009-04-02 2018-02-26 Colucid Pharmaceuticals, Inc. 2,4,6-trifluor-n-[6-(1-metil-piperidin-4-karbonil)-piridin-2-il]-benzamidas, skirtas migrenos gydymui peroraliniu ar intraveniniu keliu
WO2011123654A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
WO2012163365A1 (en) 2011-06-01 2012-12-06 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CN113173910A (zh) 2016-07-15 2021-07-27 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
CO2019005290A2 (es) 2019-05-31
KR20230008257A (ko) 2023-01-13
ECSP19040190A (es) 2019-08-30
RS62415B1 (sr) 2021-10-29
ES2889476T3 (es) 2022-01-12
CR20190251A (es) 2019-08-26
MX2021014139A (es) 2022-05-24
EA201991112A1 (ru) 2019-10-31
DOP2019000139A (es) 2019-08-15
HUE056820T2 (hu) 2022-03-28
MY196855A (en) 2023-05-05
PL3551617T3 (pl) 2021-12-20
CN115385894A (zh) 2022-11-25
ZA201903449B (en) 2021-02-24
US11053214B2 (en) 2021-07-06
TN2019000174A1 (en) 2020-10-05
IL266598B1 (en) 2024-01-01
MX388091B (es) 2025-03-19
MD3551617T2 (ro) 2021-12-31
KR20250070124A (ko) 2025-05-20
US20200087279A1 (en) 2020-03-19
PH12019501252B1 (en) 2024-05-24
MA52920B1 (fr) 2021-11-30
CY1124540T1 (el) 2022-07-22
KR20190075130A (ko) 2019-06-28
TWI671290B (zh) 2019-09-11
JP2023123678A (ja) 2023-09-05
AU2017373784A1 (en) 2019-05-16
DK3551617T3 (da) 2021-09-13
PT3551617T (pt) 2021-10-04
CA3043772C (en) 2022-06-07
PH12019501252A1 (en) 2019-12-02
LT3551617T (lt) 2021-10-11
PE20191134A1 (es) 2019-09-02
JP2020500936A (ja) 2020-01-16
JP2024178323A (ja) 2024-12-24
HRP20211557T1 (hr) 2022-01-07
NZ752906A (en) 2021-07-30
PE20241297A1 (es) 2024-06-24
TW201833097A (zh) 2018-09-16
EP3551617A1 (en) 2019-10-16
EP3551617B1 (en) 2021-08-11
MX392547B (es) 2025-03-24
IL266598A (en) 2019-07-31
JOP20190129B1 (ar) 2023-03-28
IL266598B2 (en) 2024-05-01
JP2022000451A (ja) 2022-01-04
JOP20190129A1 (ar) 2019-05-29
JP7561240B2 (ja) 2024-10-03
KR20210102497A (ko) 2021-08-19
CN115385893A (zh) 2022-11-25
CA3043772A1 (en) 2018-06-14
AU2017373784B2 (en) 2020-04-23
SI3551617T1 (sl) 2021-11-30
MA52920A (fr) 2021-04-28
WO2018106657A1 (en) 2018-06-14
MX2019006520A (es) 2019-08-21
BR112019010934A2 (pt) 2019-10-01
UA124433C2 (uk) 2021-09-15
CN110291079A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
CL2019001426A1 (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
MX2023000745A (es) Composiciones para usarse en el suministro de agentes biomacromoleculares.
CL2019001344A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2019014228A (es) Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
UY37018A (es) Inhibidores bicíclicos de pad4
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2018003301A (es) Inhibidores de pcna.
CO2019014647A2 (es) Composiciones inmunogénicas
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
BR112017004552A2 (pt) composições farmacêuticas